CSPG4 and acute lymphoblastic leukemia: Importantly, clinical data from MLLr-BCP-ALL infants (n = 55) uniformly enrolled in the Interfant treatment protocol reveals that patients with refractory or relapsed disease initially had at diagnosis 28% more NG2-expressing blasts than those patients not experiencing relapse (53% vs. 41%, p > 0.05).